SBL
NVAX icon

Sargent Bickham Lagudis’s Novavax NVAX Stock Holding History

Sargent Bickham Lagudis’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$411 Hold
40
– – ﹤0.01% 994
2022
Q3 		$1K Hold
40
– – ﹤0.01% 938
2022
Q2 		$2K Buy
+40
New +$2.07K ﹤0.01% 938
2020
Q4 		– Sell
-720
Closed -$78K – 900
2020
Q3 		$78K Buy
+720
New +$87.7K 0.01% 328

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIG
Herr Investment Group Austin, Texas $1.5B AUM 29.27% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sargent Bickham Lagudis's NVAX Position: Q4 2022 in Review

Sargent Bickham Lagudis held its Novavax (NVAX) position steady in Q4 2022 at 40 shares worth $411. The position accounts for ﹤0.01% of the portfolio, ranked #994.

Sargent Bickham Lagudis first reported a position in NVAX in Q3 2020 and has held it in 4 quarters since. The position peaked at $78K in Q3 2020. 252 funds tracked by Wall St. Rank hold NVAX as of Q4 2022.

  • Sargent Bickham Lagudis held 40 shares of Novavax worth $411 as of Q4 2022.
  • Sargent Bickham Lagudis left its Novavax share count unchanged in Q4 2022.
  • Novavax made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #994 holding.
  • Sargent Bickham Lagudis first reported a position in Novavax in Q3 2020 and has held it in 4 quarters since.
  • Sargent Bickham Lagudis's Novavax position peaked at $78K in Q3 2020.
  • 252 funds tracked by Wall St. Rank held Novavax as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.